Since our findings indicate that ganetespib induces the degradation of ErbB2 in ErbB2+ breast cancer cells (Fig. 5), we aimed to determine whether ErbB2-overexpressing cancer cells are more sensitive to ganetespib than ErbB2-negative cells. Here, ERBB2 is linked to cancer.